欧洲委员会批准托利帕利马布治疗NPC和先进的ESCC,这是NPC的第一种药物,是先进的ESCC的第一线治疗. European Commission approves toripalimab for NPC and advanced ESCC, first drug for NPC, first-line treatment for advanced ESCC.

欧洲联盟委员会批准了上海Junshi生物科学开发的Toripalimab(Loqtorzi),用于两种癌症治疗:经常性的、无法手术的鼻阴道癌和无法剖析的先进食道结膜细胞癌。 The European Commission has approved toripalimab (Loqtorzi®), developed by Shanghai Junshi Biosciences, for two cancer treatments: recurrent, inoperable nasopharyngeal carcinoma (NPC) and unresectable advanced esophageal squamous cell carcinoma (ESCC). 无论PD- L1状态如何,它是欧洲首款针对NPC的药物,也是先进ESCC的第一线治疗. It is the first drug in Europe for NPC and the first-line treatment for advanced ESCC, regardless of PD-L1 status. 这一批准是在第三阶段临床试验取得积极成果后作出的,显示存活率有所提高。 The approval follows positive results from Phase III clinical trials, showing improved survival rates.